ログイン

ISBB

ISBB
50問 • 2年前
  • Yves Laure Pimentel
  • 通報

    問題一覧

  • 1

    What is the component of choice for a patient with chronic granulomatous disease (CGD)? - A. Fresh frozen plasma (FFP) - B. Granulocytes - C. Cryoprecipitate - D. RBCs

    B. Granulocytes

  • 2

    What method can be employed to detect bacteria in random donor platelets? ] - A. pH - B. Glucose - C. Pan-genera detection (PGD) assay - D. Gram stain

    C. Pan-genera detection (PGD) assay

  • 3

    : All of the following statements regarding FFP are true, except: - A. FFP must be prepared within 24 hours of collection - B. After thawing, FFP must be transfused within 24 hours - C. Storage temperature for FFP with a 1-year shelf life is –18°C or less - D. When thawed, FFP must be stored between 1°C to 6°C

    FFP must be prepared within 24 hours of collection

  • 4

    What may be done to RBCs before transfusion to a patient with cold agglutinin disease to reduce the possibility of a transfusion reaction? ] - A. Irradiate to prevent graft-versus-host-disease (GVHD) - B. Wash with 0.9% saline - C. Warm to 37°C with a blood warmer - D. Transport so that temperature is maintained at 20°C to 24°C

    C. Warm to 37°C with a blood warmer

  • 5

    : A unit of packed RBCs is split using the open system. One of the half units is used. What may be done with the second half unit? ] - A. Must be issued within 24 hours - B. Must be issued within 48 hours - C. Must be irradiated - D. Must retain the original expiration date

    A. Must be issued within 24 hours

  • 6

    What should be done if a noticeable clot is found in an RBC unit? - A. Issue the unit; the blood will be filtered - B. Issue the unit; note the presence of a clot on the release form - C. Filter the unit in the blood bank before issue - D. Do not issue the unit

    D. Do not issue the unit

  • 7

    : Cryoprecipitate may be used to treat all of the following, except: - A. von Willebrand disease - B. Hypofibrinogenemia - C. Idiopathic thrombocytopenic purpura (ITP) - D. Factor XIII deficiency

    C. Idiopathic thrombocytopenic purpura (ITP)

  • 8

    What component(s) is (are) indicated for patients who have anti-IgA antibodies? - A. Whole blood - B. Packed RBCs - C. Washed or deglycerolized RBCs - D. Granulocytes

    Washed or deglycerolized RBCs

  • 9

    What is the expiration date for pooled cryoprecipitate (pooled before freezing)? - A. 12 months from latest date of collection of product in pool - B. 12 months from earliest date of collection of product in pool - C. 4 hours - D. 6 hours

    B. 12 months from earliest date of collection of product in pool

  • 10

    All of the following are true regarding washed RBCs, except: - A. RBCs are washed with 1 to 2 L of normal saline - B. Volume is 180 mL - C. Shelf life is extended - D. Leukocytes are removed

    C. Shelf life is extended

  • 11

    Which component has the longest expiration date? - A. Cryoprecipitate - B. FFP - C. Frozen RBCs - D. Platelet concentrates

    C. Frozen RBCs

  • 12

    : All of the following are advantages of using single-donor platelets as opposed to random donor platelets, except: - A. Less preparation time - . Less antigen exposure for patients - C. May be HLA matched - D. No pooling is required

    A. Less preparation time

  • 13

    What is the expiration of cryoprecipitate once pooled without the use of a sterile connecting device? - A. 4 hours - B. 6 hours - C. 8 hours - D. 24 hours

    A. 4 hours

  • 14

    All of the following are reasons for a positive DAT on cord blood cells of a newborn except: - A. High concentrations of Wharton jelly on cord blood cells - B. Immune anti-A from an O mother on the cells of an A baby - C. Immune anti-D from an Rh negative mother on the cells of an Rh-positive baby - D. Immune anti-K from a K-negative mother on the cells of a K-negative baby

    D. Immune anti-K from a K-negative mother on the cells of a K-negative baby

  • 15

    A fetal screen yielded negative results on a mother who is O negative and infant who is O positive. What course of action should be taken? ] - A. Perform a Kleihauer-Betke test - B. Issue one full dose of RhIg - C. Perform a DAT on the infant - D. Perform an antibody screen on the mother

    B. Issue one full dose of RhIg

  • 16

    What should be done when a woman who is 24 weeks pregnant has a positive antibody screen? ] - A. Perform an antibody identification panel; titer, if necessary - B. No need to do anything until 30 weeks’ gestation - C. Administer RhIg - D. Adsorb the antibody onto antigen-positive cells

    A. Perform an antibody identification panel; titer, if necessary

  • 17

    : All of the following are interventions for fetal distress caused by maternal antibodies attacking fetal cells except: ] - A. Intrauterine transfusion - B. Plasmapheresis on the mother - C. Transfusion of antigen-positive cells to the mother - D. Middle cerebral artery peak systolic velocity (MCA-PSV)

    C. Transfusion of antigen-positive cells to the mother

  • 18

    Cord blood cells are washed six times with saline, and the DAT result and negative control are still positive. What should be done next? ] - A. Obtain a heelstick sample - B. Record the DAT result as positive - C. Obtain another cord blood sample - D. Perform elution on the cord blood cells

    A. Obtain a heelstick sample

  • 19

    What is the correct procedure upon receipt of a test request for human chorionic gonadotropin (hCG) on the serum of a 60-year-old man? ] - A. Return the request; hCG is not performed on men - B. Perform a qualitative hCG test to see if hCG is present - C. Perform the test; hCG may be increased in testicular tumors - D. Perform the test but use different standards and controls

    C. Perform the test; hCG may be increased in testicular tumors

  • 20

    Would an hCG test using a monoclonal antibody against the β-subunit of hCG likely be affected by an increased level of follicle-stimulating hormone (FSH)? ] - A. Yes, the β-subunit of FSH is identical to that of hCG - B. No, the test would be specific for the β-subunit of hCG - C. Yes, a cross reaction would occur because of structural similarities - D. No, the structure of FSH and hCG are not at all similar

    B. No, the test would be specific for the β-subunit of hCG

  • 21

    Which of the following substances, sometimes used as a tumor marker, is increased two or threefold in a normal pregnancy? ] - A. Alkaline phosphatase (ALP) - B. Calcitonin - C. Adrenocortocotropic hormone (ACTH) - D. Neuron-specific enolase

    A. Alkaline phosphatase (ALP)

  • 22

    What is an advantage of performing a prostate-specific antigen (PSA) test for prostate cancer? ] - A. PSA is stable in serum and not affected by digital rectal examination - B. PSA is increased only in prostatic malignancy - C. A normal serum level rules out malignant prostatic disease - D. The percentage of free PSA is elevated in persons with malignant disease

    A. PSA is stable in serum and not affected by digital rectal examination

  • 23

    Which method is the most sensitive for quantitation of AFP ] - A. Double immunodiffusion - B. Electrophoresis - C. Enzyme immunoassay - D. Particle agglutination

    C. Enzyme immunoassay

  • 24

    How is HLA typing used in the investigation of genetic diseases? - A. For prediction of the severity of the disease - B. For genetic linkage studies - C. For direct diagnosis of disease - D. Is not useful in this situation

    B. For genetic linkage studies

  • 25

    Select the best donor for a man, blood type AB, in need of kidney transplantation. ] - A. His brother, type AB, HLA matched for class II antigens - B. His mother, type B, HLA matched for class I antigens - C. His cousin, type O, HLA matched for major class II antigens - D. Deceased donor, type O, HLA matched for some class I and II antigens

    A. His brother, type AB, HLA matched for class II antigens

  • 26

    Interpret the following microcytotoxicity target cell results: A9 and B12 cells = damaged; A1 and Aw19 cells = intact. ] - A. Positive for A1 and Aw19; negative for A9 and B12 - B. Negative for A1 and Aw19; positive for A9 and B12 - C. Error in test system; retest - D. Impossible to determine

    B. Negative for A1 and Aw19; positive for A9 and B12

  • 27

    Which method, classically used for HLA-D typing, is often used to determine the compatibility between a living organ donor and a recipient? ] - A. Flow cytometry - B. Mixed lymphocyte culture (MLC) - C. Primed lymphocyte test - D. Restriction fragment length polymorphism (RFLP)

    B. Mixed lymphocyte culture (MLC)

  • 28

    The most effective component to treat a patient with fibrinogen deficiency is: - A. Fresh Frozen Plasma - B. Platelets - D. Cryoprecipitate - C. Fresh Whole Blood

    D. Cryoprecipitate

  • 29

    . The major immunoglobulin class(es) of anti-B in a group A individual is (are): ] - IgM - IgG - IgM and IgG - IgM and IgA

    IgM

  • 30

    : Which of the following best describes ANCA? ] - Anti-nuclear cell antibodies - Anti-neurological cytoplasmic antigens - Anti-neutrophilic cytoplasmic antibodies - Anti-nucleic acid complex antigens

    Anti-neutrophilic cytoplasmic antibodies

  • 31

    .. What is the second leading cause of death in systemic lupus erythematosus (SLE) patients? ] - Kidney failure - Infections - Stroke - Heart disease

    Heart disease

  • 32

    ... How many RDPs are required to increase a pre-transfusion platelet count of 135,000/ul to a 150,000/ul post-transfusion platelet count? ] - 1 - 2 - 3 - 4

    3

  • 33

    Blocked Rh remedy ] - Elution - Absorption - Adsorption - Recentrifugation of the blood sample

    Elution

  • 34

    ... Karyotyping must be performed during ] - Metaphase - Prophase - Telophase - Anaphase

    Metaphase

  • 35

    ..... First molecular marker to increase in the early Hepa B infection ] - HBV DNA - HbsAg - Surface Antigen - Both B and C

    HBV DNA

  • 36

    ...... First serological marker to increase during Hepa B infection ] - HbsAg - HbeAg - HbfAg - HbcAg

    HbsAg

  • 37

    A test for Type 1 hypersensitivity ] - Mantoux mtd - Prausnitz-Kustner rxn - Coomb's test - 54% Patch test

    Prausnitz-Kustner rxn

  • 38

    in flourescent immunoassay, this fluorochrome exhibits apple green color ] - FITC - TRITC - FCTIT

    - FITC

  • 39

    most common autoimmune liver dsx ] - primary biliary cirrhosis - SLE - primary sclerosing cholangitis - autoimmune hepa

    primary biliary cirrhosis

  • 40

    : Which two organs are considered the primary lymphoid organs in which immunocompetent cells originate and mature? - Thyroid and Peyer patches - Thymus and bone marrow - Spleen and mucosal-associated lymphoid tissue (MALT) - Lymph nodes and thoracic duct

    Thymus and bone marrow

  • 41

    : What type of B cells is formed after antigen stimulation? - Plasma cells and memory B cells - Mature B cells - Antigen-dependent B cells - Receptor-activated B cells

    Plasma cells and memory B cells

  • 42

    Which cluster of differentiation (CD) marker is the most specific identifying marker for mature T cells? - CD1 - CD2 - CD3 - CD4 or CD8

    CD2

  • 43

    : Which markers are found on mature, peripheral helper T cells? - CD1, CD2, CD4 - CD2, CD3, CD8 - CD1, CD3, CD4 - CD2, CD3, CD4

    CD2, CD3, CD4

  • 44

    What is the name of the process by which phagocytic cells are attracted to a substance, such as a bacterial peptide? - Diapedesis - Degranulation - Chemotaxis - Phagotaxis

    Chemotaxis

  • 45

    All of the following are immunologic functions of complement EXCEPT: - Inducion of an antiviral state - Opsonization - Chemotaxis - Anaphylatoxin formation

    Inducion of an antiviral sta

  • 46

    : Which complement component is found in both the classic and alternative pathways? - C1 - C4 - FACTOR D - C3

    C3

  • 47

    Which T cells express the CD8 marker and act specifically to kill tumors or virally infected cells? - Helper T cells - Suppressor T cells - Cytotoxic T cells (TC cells) - Regulator T cells

    Cytotoxic T cells (TC cells)

  • 48

    : How are TC cells and natural killer (NK) cells similar? - A. Require antibody to be present - B. Effective against virally infected cells - C. Recognize antigen in association with human leukocyte antigen (HLA) class II markers - D. Do not bind to infected cells

    B. Effective against virally infected cells

  • 49

    Which of the following is not a viable method for removing leukocytes from RBCs? ] - A. Prestorage filtration - B. Bedside filtration - C. Poststorage filtration - D. Buffy coat removal

    D. Buffy coat removal

  • 50

    : A unit of whole blood is collected at 10:00 a.m. and stored at 20°C to 24°C. What is the last hour at which platelet concentrates may be made from this unit? - A. 4:00 p.m. - B. 6:00 p.m. - C. 7:00 p.m. - D. 8:00 p.m.

    B. 6:00 p.m.

  • HTMLBE

    HTMLBE

    Yves Laure Pimentel · 64問 · 2年前

    HTMLBE

    HTMLBE

    64問 • 2年前
    Yves Laure Pimentel

    PARASITOLOGY

    PARASITOLOGY

    Yves Laure Pimentel · 111問 · 2年前

    PARASITOLOGY

    PARASITOLOGY

    111問 • 2年前
    Yves Laure Pimentel

    other names parasitology

    other names parasitology

    Yves Laure Pimentel · 70問 · 2年前

    other names parasitology

    other names parasitology

    70問 • 2年前
    Yves Laure Pimentel

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    Yves Laure Pimentel · 61問 · 2年前

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    61問 • 2年前
    Yves Laure Pimentel

    HISTOPATHOLOGY

    HISTOPATHOLOGY

    Yves Laure Pimentel · 69問 · 2年前

    HISTOPATHOLOGY

    HISTOPATHOLOGY

    69問 • 2年前
    Yves Laure Pimentel

    CC-2 SPECTROPHOTOMETRY

    CC-2 SPECTROPHOTOMETRY

    Yves Laure Pimentel · 100問 · 2年前

    CC-2 SPECTROPHOTOMETRY

    CC-2 SPECTROPHOTOMETRY

    100問 • 2年前
    Yves Laure Pimentel

    CC-3 ELECTROPHORESIS

    CC-3 ELECTROPHORESIS

    Yves Laure Pimentel · 41問 · 2年前

    CC-3 ELECTROPHORESIS

    CC-3 ELECTROPHORESIS

    41問 • 2年前
    Yves Laure Pimentel

    AUBF LAB SAFETY

    AUBF LAB SAFETY

    Yves Laure Pimentel · 87問 · 2年前

    AUBF LAB SAFETY

    AUBF LAB SAFETY

    87問 • 2年前
    Yves Laure Pimentel

    CSF 1

    CSF 1

    Yves Laure Pimentel · 100問 · 2年前

    CSF 1

    CSF 1

    100問 • 2年前
    Yves Laure Pimentel

    CSF 2

    CSF 2

    Yves Laure Pimentel · 82問 · 2年前

    CSF 2

    CSF 2

    82問 • 2年前
    Yves Laure Pimentel

    SEMEN 1

    SEMEN 1

    Yves Laure Pimentel · 100問 · 2年前

    SEMEN 1

    SEMEN 1

    100問 • 2年前
    Yves Laure Pimentel

    SEMEN 2

    SEMEN 2

    Yves Laure Pimentel · 7問 · 2年前

    SEMEN 2

    SEMEN 2

    7問 • 2年前
    Yves Laure Pimentel

    SYNOVIAL FLUID 1

    SYNOVIAL FLUID 1

    Yves Laure Pimentel · 100問 · 2年前

    SYNOVIAL FLUID 1

    SYNOVIAL FLUID 1

    100問 • 2年前
    Yves Laure Pimentel

    SYNOVIAL FLUID 2

    SYNOVIAL FLUID 2

    Yves Laure Pimentel · 6問 · 2年前

    SYNOVIAL FLUID 2

    SYNOVIAL FLUID 2

    6問 • 2年前
    Yves Laure Pimentel

    SEROUS FLUID

    SEROUS FLUID

    Yves Laure Pimentel · 25問 · 2年前

    SEROUS FLUID

    SEROUS FLUID

    25問 • 2年前
    Yves Laure Pimentel

    PLEURAL FLUID

    PLEURAL FLUID

    Yves Laure Pimentel · 44問 · 2年前

    PLEURAL FLUID

    PLEURAL FLUID

    44問 • 2年前
    Yves Laure Pimentel

    PERICARDIAL FLUID

    PERICARDIAL FLUID

    Yves Laure Pimentel · 18問 · 2年前

    PERICARDIAL FLUID

    PERICARDIAL FLUID

    18問 • 2年前
    Yves Laure Pimentel

    PERITONEAL FLUID/ ASCITIC FLUID

    PERITONEAL FLUID/ ASCITIC FLUID

    Yves Laure Pimentel · 30問 · 2年前

    PERITONEAL FLUID/ ASCITIC FLUID

    PERITONEAL FLUID/ ASCITIC FLUID

    30問 • 2年前
    Yves Laure Pimentel

    AMNIOTIC FLUID

    AMNIOTIC FLUID

    Yves Laure Pimentel · 92問 · 2年前

    AMNIOTIC FLUID

    AMNIOTIC FLUID

    92問 • 2年前
    Yves Laure Pimentel

    FECALYSIS

    FECALYSIS

    Yves Laure Pimentel · 80問 · 2年前

    FECALYSIS

    FECALYSIS

    80問 • 2年前
    Yves Laure Pimentel

    OTHER BODY FLUIDS

    OTHER BODY FLUIDS

    Yves Laure Pimentel · 89問 · 2年前

    OTHER BODY FLUIDS

    OTHER BODY FLUIDS

    89問 • 2年前
    Yves Laure Pimentel

    MTLBE- SUHO NOTES

    MTLBE- SUHO NOTES

    Yves Laure Pimentel · 86問 · 2年前

    MTLBE- SUHO NOTES

    MTLBE- SUHO NOTES

    86問 • 2年前
    Yves Laure Pimentel

    MTLBE..

    MTLBE..

    Yves Laure Pimentel · 35問 · 2年前

    MTLBE..

    MTLBE..

    35問 • 2年前
    Yves Laure Pimentel

    CC- CHROMATOGRAPHY

    CC- CHROMATOGRAPHY

    Yves Laure Pimentel · 19問 · 1年前

    CC- CHROMATOGRAPHY

    CC- CHROMATOGRAPHY

    19問 • 1年前
    Yves Laure Pimentel

    CC-OSMOMETRY

    CC-OSMOMETRY

    Yves Laure Pimentel · 14問 · 1年前

    CC-OSMOMETRY

    CC-OSMOMETRY

    14問 • 1年前
    Yves Laure Pimentel

    CC-ELECTROCHEMISTRY TECHNIQUES

    CC-ELECTROCHEMISTRY TECHNIQUES

    Yves Laure Pimentel · 43問 · 1年前

    CC-ELECTROCHEMISTRY TECHNIQUES

    CC-ELECTROCHEMISTRY TECHNIQUES

    43問 • 1年前
    Yves Laure Pimentel

    CC- CARBOHYDRATES

    CC- CARBOHYDRATES

    Yves Laure Pimentel · 49問 · 2年前

    CC- CARBOHYDRATES

    CC- CARBOHYDRATES

    49問 • 2年前
    Yves Laure Pimentel

    CC- DIABETES MELLITUS

    CC- DIABETES MELLITUS

    Yves Laure Pimentel · 97問 · 2年前

    CC- DIABETES MELLITUS

    CC- DIABETES MELLITUS

    97問 • 2年前
    Yves Laure Pimentel

    MAJOR LIPOPROTEINS

    MAJOR LIPOPROTEINS

    Yves Laure Pimentel · 57問 · 2年前

    MAJOR LIPOPROTEINS

    MAJOR LIPOPROTEINS

    57問 • 2年前
    Yves Laure Pimentel

    MINOR LIPOPROTEINS

    MINOR LIPOPROTEINS

    Yves Laure Pimentel · 63問 · 2年前

    MINOR LIPOPROTEINS

    MINOR LIPOPROTEINS

    63問 • 2年前
    Yves Laure Pimentel

    PROTEINS

    PROTEINS

    Yves Laure Pimentel · 37問 · 2年前

    PROTEINS

    PROTEINS

    37問 • 2年前
    Yves Laure Pimentel

    PLASMA PROTEINS 1

    PLASMA PROTEINS 1

    Yves Laure Pimentel · 91問 · 2年前

    PLASMA PROTEINS 1

    PLASMA PROTEINS 1

    91問 • 2年前
    Yves Laure Pimentel

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    Yves Laure Pimentel · 98問 · 2年前

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    98問 • 2年前
    Yves Laure Pimentel

    MISCELLANEOUS PROTEINS

    MISCELLANEOUS PROTEINS

    Yves Laure Pimentel · 61問 · 2年前

    MISCELLANEOUS PROTEINS

    MISCELLANEOUS PROTEINS

    61問 • 2年前
    Yves Laure Pimentel

    Liver Function Test 1

    Liver Function Test 1

    Yves Laure Pimentel · 100問 · 2年前

    Liver Function Test 1

    Liver Function Test 1

    100問 • 2年前
    Yves Laure Pimentel

    Liver Function Test 2

    Liver Function Test 2

    Yves Laure Pimentel · 96問 · 2年前

    Liver Function Test 2

    Liver Function Test 2

    96問 • 2年前
    Yves Laure Pimentel

    TUMOR MARKERS

    TUMOR MARKERS

    Yves Laure Pimentel · 33問 · 2年前

    TUMOR MARKERS

    TUMOR MARKERS

    33問 • 2年前
    Yves Laure Pimentel

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    Yves Laure Pimentel · 41問 · 2年前

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    41問 • 2年前
    Yves Laure Pimentel

    GLYCOGEN STORAGE DISEASES

    GLYCOGEN STORAGE DISEASES

    Yves Laure Pimentel · 17問 · 2年前

    GLYCOGEN STORAGE DISEASES

    GLYCOGEN STORAGE DISEASES

    17問 • 2年前
    Yves Laure Pimentel

    LIPID STORAGE DISEASES

    LIPID STORAGE DISEASES

    Yves Laure Pimentel · 14問 · 2年前

    LIPID STORAGE DISEASES

    LIPID STORAGE DISEASES

    14問 • 2年前
    Yves Laure Pimentel

    PROTEINS

    PROTEINS

    Yves Laure Pimentel · 71問 · 2年前

    PROTEINS

    PROTEINS

    71問 • 2年前
    Yves Laure Pimentel

    QUICK FIRE- ELECTRODES

    QUICK FIRE- ELECTRODES

    Yves Laure Pimentel · 7問 · 2年前

    QUICK FIRE- ELECTRODES

    QUICK FIRE- ELECTRODES

    7問 • 2年前
    Yves Laure Pimentel

    ELECTROLYTES

    ELECTROLYTES

    Yves Laure Pimentel · 10問 · 2年前

    ELECTROLYTES

    ELECTROLYTES

    10問 • 2年前
    Yves Laure Pimentel

    DRUGS

    DRUGS

    Yves Laure Pimentel · 27問 · 2年前

    DRUGS

    DRUGS

    27問 • 2年前
    Yves Laure Pimentel

    TOXIC AGENTS:

    TOXIC AGENTS:

    Yves Laure Pimentel · 12問 · 2年前

    TOXIC AGENTS:

    TOXIC AGENTS:

    12問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    Yves Laure Pimentel · 100問 · 2年前

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    100問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY (HEMATOPOIESIS 2)

    HEMATOLOGY (HEMATOPOIESIS 2)

    Yves Laure Pimentel · 29問 · 2年前

    HEMATOLOGY (HEMATOPOIESIS 2)

    HEMATOLOGY (HEMATOPOIESIS 2)

    29問 • 2年前
    Yves Laure Pimentel

    hema diseases

    hema diseases

    Yves Laure Pimentel · 25問 · 2年前

    hema diseases

    hema diseases

    25問 • 2年前
    Yves Laure Pimentel

    AML

    AML

    Yves Laure Pimentel · 43問 · 2年前

    AML

    AML

    43問 • 2年前
    Yves Laure Pimentel

    GLOBIN SYNTHESIS

    GLOBIN SYNTHESIS

    Yves Laure Pimentel · 71問 · 2年前

    GLOBIN SYNTHESIS

    GLOBIN SYNTHESIS

    71問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY REFERENCE RANGES

    HEMATOLOGY REFERENCE RANGES

    Yves Laure Pimentel · 31問 · 2年前

    HEMATOLOGY REFERENCE RANGES

    HEMATOLOGY REFERENCE RANGES

    31問 • 2年前
    Yves Laure Pimentel

    DISORDERS OF PRIMARY HEMOSTASIS

    DISORDERS OF PRIMARY HEMOSTASIS

    Yves Laure Pimentel · 34問 · 2年前

    DISORDERS OF PRIMARY HEMOSTASIS

    DISORDERS OF PRIMARY HEMOSTASIS

    34問 • 2年前
    Yves Laure Pimentel

    PLATELET DISORDERS

    PLATELET DISORDERS

    Yves Laure Pimentel · 37問 · 2年前

    PLATELET DISORDERS

    PLATELET DISORDERS

    37問 • 2年前
    Yves Laure Pimentel

    CHARACTERISTICS OF CLOTTING FACTORS

    CHARACTERISTICS OF CLOTTING FACTORS

    Yves Laure Pimentel · 100問 · 2年前

    CHARACTERISTICS OF CLOTTING FACTORS

    CHARACTERISTICS OF CLOTTING FACTORS

    100問 • 2年前
    Yves Laure Pimentel

    4. CLASSIFICATION OF MACROPHAGE

    4. CLASSIFICATION OF MACROPHAGE

    Yves Laure Pimentel · 12問 · 2年前

    4. CLASSIFICATION OF MACROPHAGE

    4. CLASSIFICATION OF MACROPHAGE

    12問 • 2年前
    Yves Laure Pimentel

    3. NATURAL OR INNATE IMMUNITY

    3. NATURAL OR INNATE IMMUNITY

    Yves Laure Pimentel · 39問 · 2年前

    3. NATURAL OR INNATE IMMUNITY

    3. NATURAL OR INNATE IMMUNITY

    39問 • 2年前
    Yves Laure Pimentel

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    Yves Laure Pimentel · 55問 · 2年前

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    55問 • 2年前
    Yves Laure Pimentel

    6. PHAGOCYTOSIS Chemotaxis

    6. PHAGOCYTOSIS Chemotaxis

    Yves Laure Pimentel · 37問 · 2年前

    6. PHAGOCYTOSIS Chemotaxis

    6. PHAGOCYTOSIS Chemotaxis

    37問 • 2年前
    Yves Laure Pimentel

    8. NATURE OF ANTIGEN

    8. NATURE OF ANTIGEN

    Yves Laure Pimentel · 44問 · 2年前

    8. NATURE OF ANTIGEN

    8. NATURE OF ANTIGEN

    44問 • 2年前
    Yves Laure Pimentel

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    Yves Laure Pimentel · 50問 · 2年前

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    50問 • 2年前
    Yves Laure Pimentel

    1. HISTORY

    1. HISTORY

    Yves Laure Pimentel · 69問 · 2年前

    1. HISTORY

    1. HISTORY

    69問 • 2年前
    Yves Laure Pimentel

    2. TYPES OF IMMUNITY

    2. TYPES OF IMMUNITY

    Yves Laure Pimentel · 38問 · 2年前

    2. TYPES OF IMMUNITY

    2. TYPES OF IMMUNITY

    38問 • 2年前
    Yves Laure Pimentel

    7. PHAGOCYTOSIS Engulfment and Digestion

    7. PHAGOCYTOSIS Engulfment and Digestion

    Yves Laure Pimentel · 21問 · 2年前

    7. PHAGOCYTOSIS Engulfment and Digestion

    7. PHAGOCYTOSIS Engulfment and Digestion

    21問 • 2年前
    Yves Laure Pimentel

    8. PHAGOCYTOSIS EXOCYTOSIS

    8. PHAGOCYTOSIS EXOCYTOSIS

    Yves Laure Pimentel · 15問 · 2年前

    8. PHAGOCYTOSIS EXOCYTOSIS

    8. PHAGOCYTOSIS EXOCYTOSIS

    15問 • 2年前
    Yves Laure Pimentel

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    Yves Laure Pimentel · 32問 · 2年前

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    32問 • 2年前
    Yves Laure Pimentel

    11. TRANSPLANTATION IMMUNOLOGY

    11. TRANSPLANTATION IMMUNOLOGY

    Yves Laure Pimentel · 30問 · 2年前

    11. TRANSPLANTATION IMMUNOLOGY

    11. TRANSPLANTATION IMMUNOLOGY

    30問 • 2年前
    Yves Laure Pimentel

    2. LYMPHOID ORGANS

    2. LYMPHOID ORGANS

    Yves Laure Pimentel · 38問 · 2年前

    2. LYMPHOID ORGANS

    2. LYMPHOID ORGANS

    38問 • 2年前
    Yves Laure Pimentel

    3. CLUSTER OF DIFFERENTIATION

    3. CLUSTER OF DIFFERENTIATION

    Yves Laure Pimentel · 48問 · 2年前

    3. CLUSTER OF DIFFERENTIATION

    3. CLUSTER OF DIFFERENTIATION

    48問 • 2年前
    Yves Laure Pimentel

    4. T-CELL DIFFERENTIATION

    4. T-CELL DIFFERENTIATION

    Yves Laure Pimentel · 35問 · 2年前

    4. T-CELL DIFFERENTIATION

    4. T-CELL DIFFERENTIATION

    35問 • 2年前
    Yves Laure Pimentel

    5. T CELL IMMUNODEFICIENCIES

    5. T CELL IMMUNODEFICIENCIES

    Yves Laure Pimentel · 18問 · 2年前

    5. T CELL IMMUNODEFICIENCIES

    5. T CELL IMMUNODEFICIENCIES

    18問 • 2年前
    Yves Laure Pimentel

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    Yves Laure Pimentel · 44問 · 2年前

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    44問 • 2年前
    Yves Laure Pimentel

    7. B CELL IMMUNODEFICIENCIES

    7. B CELL IMMUNODEFICIENCIES

    Yves Laure Pimentel · 23問 · 2年前

    7. B CELL IMMUNODEFICIENCIES

    7. B CELL IMMUNODEFICIENCIES

    23問 • 2年前
    Yves Laure Pimentel

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    Yves Laure Pimentel · 34問 · 2年前

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    34問 • 2年前
    Yves Laure Pimentel

    9. COMPARISON OF T AND B CELLS

    9. COMPARISON OF T AND B CELLS

    Yves Laure Pimentel · 12問 · 2年前

    9. COMPARISON OF T AND B CELLS

    9. COMPARISON OF T AND B CELLS

    12問 • 2年前
    Yves Laure Pimentel

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    Yves Laure Pimentel · 16問 · 2年前

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    16問 • 2年前
    Yves Laure Pimentel

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    Yves Laure Pimentel · 15問 · 2年前

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    15問 • 2年前
    Yves Laure Pimentel

    12. ANTIBODY

    12. ANTIBODY

    Yves Laure Pimentel · 79問 · 2年前

    12. ANTIBODY

    12. ANTIBODY

    79問 • 2年前
    Yves Laure Pimentel

    13. TYPES OF ANTIBODIES

    13. TYPES OF ANTIBODIES

    Yves Laure Pimentel · 97問 · 2年前

    13. TYPES OF ANTIBODIES

    13. TYPES OF ANTIBODIES

    97問 • 2年前
    Yves Laure Pimentel

    14. MONOCLONAL ANTIBODIES

    14. MONOCLONAL ANTIBODIES

    Yves Laure Pimentel · 11問 · 2年前

    14. MONOCLONAL ANTIBODIES

    14. MONOCLONAL ANTIBODIES

    11問 • 2年前
    Yves Laure Pimentel

    1. INTERLEUKINS

    1. INTERLEUKINS

    Yves Laure Pimentel · 23問 · 2年前

    1. INTERLEUKINS

    1. INTERLEUKINS

    23問 • 2年前
    Yves Laure Pimentel

    2. INTERFERONS

    2. INTERFERONS

    Yves Laure Pimentel · 28問 · 2年前

    2. INTERFERONS

    2. INTERFERONS

    28問 • 2年前
    Yves Laure Pimentel

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    Yves Laure Pimentel · 8問 · 2年前

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    8問 • 2年前
    Yves Laure Pimentel

    4. COMPLEMENT SYSTEM

    4. COMPLEMENT SYSTEM

    Yves Laure Pimentel · 19問 · 2年前

    4. COMPLEMENT SYSTEM

    4. COMPLEMENT SYSTEM

    19問 • 2年前
    Yves Laure Pimentel

    15. COMPLEMENT SYSTEM

    15. COMPLEMENT SYSTEM

    Yves Laure Pimentel · 76問 · 2年前

    15. COMPLEMENT SYSTEM

    15. COMPLEMENT SYSTEM

    76問 • 2年前
    Yves Laure Pimentel

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    Yves Laure Pimentel · 21問 · 2年前

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    21問 • 2年前
    Yves Laure Pimentel

    17. COMPLEMENT AND DISEASE STATES

    17. COMPLEMENT AND DISEASE STATES

    Yves Laure Pimentel · 29問 · 2年前

    17. COMPLEMENT AND DISEASE STATES

    17. COMPLEMENT AND DISEASE STATES

    29問 • 2年前
    Yves Laure Pimentel

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    Yves Laure Pimentel · 19問 · 2年前

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    19問 • 2年前
    Yves Laure Pimentel

    19. CYTOKINES

    19. CYTOKINES

    Yves Laure Pimentel · 22問 · 2年前

    19. CYTOKINES

    19. CYTOKINES

    22問 • 2年前
    Yves Laure Pimentel

    20. INTERLEUKINS

    20. INTERLEUKINS

    Yves Laure Pimentel · 24問 · 2年前

    20. INTERLEUKINS

    20. INTERLEUKINS

    24問 • 2年前
    Yves Laure Pimentel

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    Yves Laure Pimentel · 21問 · 2年前

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21問 • 2年前
    Yves Laure Pimentel

    1. SERO

    1. SERO

    Yves Laure Pimentel · 54問 · 2年前

    1. SERO

    1. SERO

    54問 • 2年前
    Yves Laure Pimentel

    2. PRECIPITATION

    2. PRECIPITATION

    Yves Laure Pimentel · 38問 · 2年前

    2. PRECIPITATION

    2. PRECIPITATION

    38問 • 2年前
    Yves Laure Pimentel

    3. PASSIVE IMMUNODIFFUSION

    3. PASSIVE IMMUNODIFFUSION

    Yves Laure Pimentel · 17問 · 2年前

    3. PASSIVE IMMUNODIFFUSION

    3. PASSIVE IMMUNODIFFUSION

    17問 • 2年前
    Yves Laure Pimentel

    4. OUCHTERLONY

    4. OUCHTERLONY

    Yves Laure Pimentel · 15問 · 2年前

    4. OUCHTERLONY

    4. OUCHTERLONY

    15問 • 2年前
    Yves Laure Pimentel

    5. ELECTROPHORETIC TECHNIQUE

    5. ELECTROPHORETIC TECHNIQUE

    Yves Laure Pimentel · 9問 · 2年前

    5. ELECTROPHORETIC TECHNIQUE

    5. ELECTROPHORETIC TECHNIQUE

    9問 • 2年前
    Yves Laure Pimentel

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    Yves Laure Pimentel · 11問 · 2年前

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    11問 • 2年前
    Yves Laure Pimentel

    7. IMMUNOFIXATION ELECTROPHORESIS

    7. IMMUNOFIXATION ELECTROPHORESIS

    Yves Laure Pimentel · 29問 · 2年前

    7. IMMUNOFIXATION ELECTROPHORESIS

    7. IMMUNOFIXATION ELECTROPHORESIS

    29問 • 2年前
    Yves Laure Pimentel

    問題一覧

  • 1

    What is the component of choice for a patient with chronic granulomatous disease (CGD)? - A. Fresh frozen plasma (FFP) - B. Granulocytes - C. Cryoprecipitate - D. RBCs

    B. Granulocytes

  • 2

    What method can be employed to detect bacteria in random donor platelets? ] - A. pH - B. Glucose - C. Pan-genera detection (PGD) assay - D. Gram stain

    C. Pan-genera detection (PGD) assay

  • 3

    : All of the following statements regarding FFP are true, except: - A. FFP must be prepared within 24 hours of collection - B. After thawing, FFP must be transfused within 24 hours - C. Storage temperature for FFP with a 1-year shelf life is –18°C or less - D. When thawed, FFP must be stored between 1°C to 6°C

    FFP must be prepared within 24 hours of collection

  • 4

    What may be done to RBCs before transfusion to a patient with cold agglutinin disease to reduce the possibility of a transfusion reaction? ] - A. Irradiate to prevent graft-versus-host-disease (GVHD) - B. Wash with 0.9% saline - C. Warm to 37°C with a blood warmer - D. Transport so that temperature is maintained at 20°C to 24°C

    C. Warm to 37°C with a blood warmer

  • 5

    : A unit of packed RBCs is split using the open system. One of the half units is used. What may be done with the second half unit? ] - A. Must be issued within 24 hours - B. Must be issued within 48 hours - C. Must be irradiated - D. Must retain the original expiration date

    A. Must be issued within 24 hours

  • 6

    What should be done if a noticeable clot is found in an RBC unit? - A. Issue the unit; the blood will be filtered - B. Issue the unit; note the presence of a clot on the release form - C. Filter the unit in the blood bank before issue - D. Do not issue the unit

    D. Do not issue the unit

  • 7

    : Cryoprecipitate may be used to treat all of the following, except: - A. von Willebrand disease - B. Hypofibrinogenemia - C. Idiopathic thrombocytopenic purpura (ITP) - D. Factor XIII deficiency

    C. Idiopathic thrombocytopenic purpura (ITP)

  • 8

    What component(s) is (are) indicated for patients who have anti-IgA antibodies? - A. Whole blood - B. Packed RBCs - C. Washed or deglycerolized RBCs - D. Granulocytes

    Washed or deglycerolized RBCs

  • 9

    What is the expiration date for pooled cryoprecipitate (pooled before freezing)? - A. 12 months from latest date of collection of product in pool - B. 12 months from earliest date of collection of product in pool - C. 4 hours - D. 6 hours

    B. 12 months from earliest date of collection of product in pool

  • 10

    All of the following are true regarding washed RBCs, except: - A. RBCs are washed with 1 to 2 L of normal saline - B. Volume is 180 mL - C. Shelf life is extended - D. Leukocytes are removed

    C. Shelf life is extended

  • 11

    Which component has the longest expiration date? - A. Cryoprecipitate - B. FFP - C. Frozen RBCs - D. Platelet concentrates

    C. Frozen RBCs

  • 12

    : All of the following are advantages of using single-donor platelets as opposed to random donor platelets, except: - A. Less preparation time - . Less antigen exposure for patients - C. May be HLA matched - D. No pooling is required

    A. Less preparation time

  • 13

    What is the expiration of cryoprecipitate once pooled without the use of a sterile connecting device? - A. 4 hours - B. 6 hours - C. 8 hours - D. 24 hours

    A. 4 hours

  • 14

    All of the following are reasons for a positive DAT on cord blood cells of a newborn except: - A. High concentrations of Wharton jelly on cord blood cells - B. Immune anti-A from an O mother on the cells of an A baby - C. Immune anti-D from an Rh negative mother on the cells of an Rh-positive baby - D. Immune anti-K from a K-negative mother on the cells of a K-negative baby

    D. Immune anti-K from a K-negative mother on the cells of a K-negative baby

  • 15

    A fetal screen yielded negative results on a mother who is O negative and infant who is O positive. What course of action should be taken? ] - A. Perform a Kleihauer-Betke test - B. Issue one full dose of RhIg - C. Perform a DAT on the infant - D. Perform an antibody screen on the mother

    B. Issue one full dose of RhIg

  • 16

    What should be done when a woman who is 24 weeks pregnant has a positive antibody screen? ] - A. Perform an antibody identification panel; titer, if necessary - B. No need to do anything until 30 weeks’ gestation - C. Administer RhIg - D. Adsorb the antibody onto antigen-positive cells

    A. Perform an antibody identification panel; titer, if necessary

  • 17

    : All of the following are interventions for fetal distress caused by maternal antibodies attacking fetal cells except: ] - A. Intrauterine transfusion - B. Plasmapheresis on the mother - C. Transfusion of antigen-positive cells to the mother - D. Middle cerebral artery peak systolic velocity (MCA-PSV)

    C. Transfusion of antigen-positive cells to the mother

  • 18

    Cord blood cells are washed six times with saline, and the DAT result and negative control are still positive. What should be done next? ] - A. Obtain a heelstick sample - B. Record the DAT result as positive - C. Obtain another cord blood sample - D. Perform elution on the cord blood cells

    A. Obtain a heelstick sample

  • 19

    What is the correct procedure upon receipt of a test request for human chorionic gonadotropin (hCG) on the serum of a 60-year-old man? ] - A. Return the request; hCG is not performed on men - B. Perform a qualitative hCG test to see if hCG is present - C. Perform the test; hCG may be increased in testicular tumors - D. Perform the test but use different standards and controls

    C. Perform the test; hCG may be increased in testicular tumors

  • 20

    Would an hCG test using a monoclonal antibody against the β-subunit of hCG likely be affected by an increased level of follicle-stimulating hormone (FSH)? ] - A. Yes, the β-subunit of FSH is identical to that of hCG - B. No, the test would be specific for the β-subunit of hCG - C. Yes, a cross reaction would occur because of structural similarities - D. No, the structure of FSH and hCG are not at all similar

    B. No, the test would be specific for the β-subunit of hCG

  • 21

    Which of the following substances, sometimes used as a tumor marker, is increased two or threefold in a normal pregnancy? ] - A. Alkaline phosphatase (ALP) - B. Calcitonin - C. Adrenocortocotropic hormone (ACTH) - D. Neuron-specific enolase

    A. Alkaline phosphatase (ALP)

  • 22

    What is an advantage of performing a prostate-specific antigen (PSA) test for prostate cancer? ] - A. PSA is stable in serum and not affected by digital rectal examination - B. PSA is increased only in prostatic malignancy - C. A normal serum level rules out malignant prostatic disease - D. The percentage of free PSA is elevated in persons with malignant disease

    A. PSA is stable in serum and not affected by digital rectal examination

  • 23

    Which method is the most sensitive for quantitation of AFP ] - A. Double immunodiffusion - B. Electrophoresis - C. Enzyme immunoassay - D. Particle agglutination

    C. Enzyme immunoassay

  • 24

    How is HLA typing used in the investigation of genetic diseases? - A. For prediction of the severity of the disease - B. For genetic linkage studies - C. For direct diagnosis of disease - D. Is not useful in this situation

    B. For genetic linkage studies

  • 25

    Select the best donor for a man, blood type AB, in need of kidney transplantation. ] - A. His brother, type AB, HLA matched for class II antigens - B. His mother, type B, HLA matched for class I antigens - C. His cousin, type O, HLA matched for major class II antigens - D. Deceased donor, type O, HLA matched for some class I and II antigens

    A. His brother, type AB, HLA matched for class II antigens

  • 26

    Interpret the following microcytotoxicity target cell results: A9 and B12 cells = damaged; A1 and Aw19 cells = intact. ] - A. Positive for A1 and Aw19; negative for A9 and B12 - B. Negative for A1 and Aw19; positive for A9 and B12 - C. Error in test system; retest - D. Impossible to determine

    B. Negative for A1 and Aw19; positive for A9 and B12

  • 27

    Which method, classically used for HLA-D typing, is often used to determine the compatibility between a living organ donor and a recipient? ] - A. Flow cytometry - B. Mixed lymphocyte culture (MLC) - C. Primed lymphocyte test - D. Restriction fragment length polymorphism (RFLP)

    B. Mixed lymphocyte culture (MLC)

  • 28

    The most effective component to treat a patient with fibrinogen deficiency is: - A. Fresh Frozen Plasma - B. Platelets - D. Cryoprecipitate - C. Fresh Whole Blood

    D. Cryoprecipitate

  • 29

    . The major immunoglobulin class(es) of anti-B in a group A individual is (are): ] - IgM - IgG - IgM and IgG - IgM and IgA

    IgM

  • 30

    : Which of the following best describes ANCA? ] - Anti-nuclear cell antibodies - Anti-neurological cytoplasmic antigens - Anti-neutrophilic cytoplasmic antibodies - Anti-nucleic acid complex antigens

    Anti-neutrophilic cytoplasmic antibodies

  • 31

    .. What is the second leading cause of death in systemic lupus erythematosus (SLE) patients? ] - Kidney failure - Infections - Stroke - Heart disease

    Heart disease

  • 32

    ... How many RDPs are required to increase a pre-transfusion platelet count of 135,000/ul to a 150,000/ul post-transfusion platelet count? ] - 1 - 2 - 3 - 4

    3

  • 33

    Blocked Rh remedy ] - Elution - Absorption - Adsorption - Recentrifugation of the blood sample

    Elution

  • 34

    ... Karyotyping must be performed during ] - Metaphase - Prophase - Telophase - Anaphase

    Metaphase

  • 35

    ..... First molecular marker to increase in the early Hepa B infection ] - HBV DNA - HbsAg - Surface Antigen - Both B and C

    HBV DNA

  • 36

    ...... First serological marker to increase during Hepa B infection ] - HbsAg - HbeAg - HbfAg - HbcAg

    HbsAg

  • 37

    A test for Type 1 hypersensitivity ] - Mantoux mtd - Prausnitz-Kustner rxn - Coomb's test - 54% Patch test

    Prausnitz-Kustner rxn

  • 38

    in flourescent immunoassay, this fluorochrome exhibits apple green color ] - FITC - TRITC - FCTIT

    - FITC

  • 39

    most common autoimmune liver dsx ] - primary biliary cirrhosis - SLE - primary sclerosing cholangitis - autoimmune hepa

    primary biliary cirrhosis

  • 40

    : Which two organs are considered the primary lymphoid organs in which immunocompetent cells originate and mature? - Thyroid and Peyer patches - Thymus and bone marrow - Spleen and mucosal-associated lymphoid tissue (MALT) - Lymph nodes and thoracic duct

    Thymus and bone marrow

  • 41

    : What type of B cells is formed after antigen stimulation? - Plasma cells and memory B cells - Mature B cells - Antigen-dependent B cells - Receptor-activated B cells

    Plasma cells and memory B cells

  • 42

    Which cluster of differentiation (CD) marker is the most specific identifying marker for mature T cells? - CD1 - CD2 - CD3 - CD4 or CD8

    CD2

  • 43

    : Which markers are found on mature, peripheral helper T cells? - CD1, CD2, CD4 - CD2, CD3, CD8 - CD1, CD3, CD4 - CD2, CD3, CD4

    CD2, CD3, CD4

  • 44

    What is the name of the process by which phagocytic cells are attracted to a substance, such as a bacterial peptide? - Diapedesis - Degranulation - Chemotaxis - Phagotaxis

    Chemotaxis

  • 45

    All of the following are immunologic functions of complement EXCEPT: - Inducion of an antiviral state - Opsonization - Chemotaxis - Anaphylatoxin formation

    Inducion of an antiviral sta

  • 46

    : Which complement component is found in both the classic and alternative pathways? - C1 - C4 - FACTOR D - C3

    C3

  • 47

    Which T cells express the CD8 marker and act specifically to kill tumors or virally infected cells? - Helper T cells - Suppressor T cells - Cytotoxic T cells (TC cells) - Regulator T cells

    Cytotoxic T cells (TC cells)

  • 48

    : How are TC cells and natural killer (NK) cells similar? - A. Require antibody to be present - B. Effective against virally infected cells - C. Recognize antigen in association with human leukocyte antigen (HLA) class II markers - D. Do not bind to infected cells

    B. Effective against virally infected cells

  • 49

    Which of the following is not a viable method for removing leukocytes from RBCs? ] - A. Prestorage filtration - B. Bedside filtration - C. Poststorage filtration - D. Buffy coat removal

    D. Buffy coat removal

  • 50

    : A unit of whole blood is collected at 10:00 a.m. and stored at 20°C to 24°C. What is the last hour at which platelet concentrates may be made from this unit? - A. 4:00 p.m. - B. 6:00 p.m. - C. 7:00 p.m. - D. 8:00 p.m.

    B. 6:00 p.m.